Recent News 82 : European Research Council awards 1.5 million euros to study RNA bacteriophages, antibiotic resistance

-

European Research Council awards 1.5 million euros to study RNA bacteriophages, antibiotic resistance

Picture taken from : https://www.labmate-online.com/news/laboratory-research-news/126/breaking-news/european-research-council-awards-15-million-euros-to-study-rna-bacteriophages-and-antibiotic-resistance/65759

Professor Jens Hör of the Helmholtz Institute for RNA-based Infection Research, Würzburg, Germany has received a prestigious European Research Council Starting Grant worth 1.5 million euros. His project, ‘RIBO-PHAGE’, will investigate ribonucleic acid bacteriophages as potential therapeutic agents against multi-resistant bacteria and explore their molecular biology to advance infection research and antimicrobial therapies

Infections caused by antibiotic-resistant bacteria pose an increasingly serious threat to global health, and science continues to search for effective alternatives to conventional antibiotics. One promising avenue of discovery are bacteriophages – or simply ‘phages’ – which are viruses that infect and destroy bacteria.

Phages attach to bacterial cells, inject their genetic material, and in so doing convert  the bacterium into a ‘factory’ for viral replication to the point where its cell wall open bursts and releases more phages to find more bacteria.

Bacteriophages are the subject of research led by Professor Hör at the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg, Germany. The institute is part of the Helmholtz Centre for Infection Research (HZI) in cooperation with Julius-Maximilians-Universität Würzburg. Hör has now received a Starting Grant of 1.5 million euros from the European Research Council (ERC) for his project, ‘RIBO-PHAGE’.

“The rising [threat of] antibiotic resistance is one of the most pressing challenges of our time. This makes it all the more gratifying that the ERC awarded a Starting Grant to junior professor Jens Hör.

“Thanks to this funding award [Hör] will be able to continue his pioneering research at the highest level,” said Professor Jörg Vogel, managing director of HIRI.

“Phages have the potential to become a game changer in everyday clinical practice, especially in the fight against multi-resistant bacteria,” said Professor Josef Penninger, Scientific Director of the HZI.

Although therapeutic uses of phages dates back to the 20th century – and in particular in the former Soviet Union – their clinical application declined after the success of antibiotics. Recent studies have revived interest in phage therapy, which has not only revealed their therapeutic promise but also provided insights into the origins of the human innate immune system.

Researchers have also reported progress in adapting phages to treat infections caused by multi-resistant bacteria.

Despite this resurgence, RNA phages – which carry ribonucleic acid rather than deoxyribonucleic acid (DNA) – remain largely unstudied.

“While DNA phages have a head and a tail, RNA phages consist only of a head,” explained Hör in how their biology differs markedly from that of DNA phages.

However, only a few RNA phages have so far been identified, and his ERC-funded project aims to define how these phages regulate their replication, exploit host mechanisms, and confront bacterial defence systems.

“Understanding these mechanisms of action facilitates the effective use of RNA phages as therapeutic agents. It also bears the potential to discover entirely novel biotechnological tools,” said Hör. His work will focus on RNA phages from the Fiersviridae and Cystoviridae families, which infect bacteria of the genera Escherichia and Pseudomonas, to map the molecular processes of infection.

Hör is the fifth HIRI group leader to have secured ERC funding. A graduate of the University of Bonn, Hör earned his doctorate from the University of Würzburg in 2020, where he studied bacterial RNA–protein complexes. He subsequently worked at the Weizmann Institute of Science, in Israel, on bacterial anti-phage defence mechanisms. Since 2024, he has led a research group at HIRI and has been a junior professor at Würzburg.

The ERC Starting Grant supports young researchers within seven years of their doctorate to establish independent careers. Grants provide up to five years of funding with a maximum of 1.5 million euros, awarded solely on the basis of scientific excellence.

Copyright belongs to, taken from : https://www.labmate-online.com/news/laboratory-research-news/126/breaking-news/european-research-council-awards-15-million-euros-to-study-rna-bacteriophages-and-antibiotic-resistance/65759

Comments

Post a Comment

Popular posts from this blog

History Part 12 : Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s)

-
Image
Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s) The period following World War II marked a decisive turning point in the trajectory of phage therapy in Western medicine. Despite the promising results bacteriophages had demonstrated prior to the war as potential antibacterial agents, the decades after 1945 saw a dramatic decline in interest, funding, and scientific engagement with phage therapy in the United States and much of Western Europe. This marginalization can be attributed to a confluence of scientific, sociopolitical, and economic factors that reshaped the landscape of infectious disease treatment and research. Artistic View One of the key contributors to this decline was the overwhelming optimism surrounding the newly discovered class of antibiotics. The post-war pharmaceutical revolution brought forward a series of broad-spectrum antibiotics such as streptomycin, tetracycline, and chloramphenicol, which were viewed as miracle drugs capable o...
Read more

The Phage Therapy in the spotlight !

-
Image
Bacteriophages: Ancient Predators and the Next Frontier in Medicine In the animated documentary The Deadliest Being on Planet Earth , the Kurzgesagt team delves into the world of bacteriophages—viruses that prey exclusively on bacteria. With vibrant visuals and precise narration, the video introduces viewers to an invisible ecosystem where microscopic hunters orchestrate life-and-death dramas that shape the biosphere. These entities, though virtually unknown to the general public, may soon become central to the future of medicine. At the heart of the video lies a paradox: bacteriophages (or "phages") are among the most abundant biological entities on Earth—outnumbering all other organisms combined—yet their therapeutic potential has been largely sidelined in the antibiotic era. The video outlines the historical trajectory of phage research, spotlighting Félix d’Hérelle’s early 20th-century work and the rise of phage therapy, only to show how it was later eclipsed by the dis...
Read more

Paper 3 : Phage Therapy May Treat Drug Resistance in Patients With Cystic Fibrosis, Study Finds

-
Image
Phage Therapy May Treat Drug Resistance in Patients With Cystic Fibrosis, Study Finds June 13, 2025 "Yale's university researchers find a new approach to combatting antimicrobial resistance. Antimicrobial resistance, in which germs like bacteria and fungi no longer respond to medicines, is a rising global threat. When antibiotics and other drugs become ineffective, infections can become difficult or impossible to treat, leading to an increase in the spread and severity of disease. In a new study, published in Nature Medicine , a team of researchers at the Center for Phage Biology and Therapy at Yale discovered a novel approach that may revolutionize the fight against antimicrobial resistance. Jon Koff, MD, with a patient Credit: Robert A. Lisak For the study, the research team investigated the use of phage therapy—the use of viruses, or phages, to target and kill bacteria—to help patients with cystic fibrosis, a disease in which antimicrobial resistance is a significant issue....
Read more